First Time Loading...
S

Santhera Pharmaceuticals Holding AG
SIX:SANN

Watchlist Manager
Santhera Pharmaceuticals Holding AG
SIX:SANN
Watchlist
Price: 9.33 CHF -0.43%
Updated: May 3, 2024
Section:
 

Wall Street
Price Targets

SANN Price Targets Summary
Santhera Pharmaceuticals Holding AG

Wall Street analysts forecast SANN stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for SANN is 30.6 CHF with a low forecast of 30.3 CHF and a high forecast of 31.5 CHF.

SANN Lowest Forecast
Wall Street Target
30.3 CHF
225% Upside
SANN Average Forecast
Wall Street Target
30.6 CHF
228% Upside
SANN Highest Forecast
Wall Street Target
31.5 CHF
238% Upside
Lowest
Price Target
30.3 CHF
225% Upside
Average
Price Target
30.6 CHF
228% Upside
Highest
Price Target
31.5 CHF
238% Upside
Santhera Pharmaceuticals Holding AG Competitors:
Price Targets
ZYME
Zymeworks Inc
76% Upside
PYC
PYC Therapeutics Ltd
240% Upside
BBIO
BridgeBio Pharma Inc
83% Upside
L
2157
Lepu Biopharma Co Ltd
39% Downside
ZYME
Zymeworks Inc
76% Upside
PYC
PYC Therapeutics Ltd
240% Upside
BBIO
BridgeBio Pharma Inc
83% Upside
L
2157
Lepu Biopharma Co Ltd
39% Downside
M
MAB
Mabion SA
3% Downside
NBIX
Neurocrine Biosciences Inc
12% Upside
SOBI
Swedish Orphan Biovitrum AB (publ)
25% Upside
GNS
Genus PLC
54% Upside

Revenue
Forecast

Revenue Estimate
Santhera Pharmaceuticals Holding AG

For the last 8 years the compound annual growth rate for Santhera Pharmaceuticals Holding AG's revenue is 14%. The projected CAGR for the next 4 years is 107%.

14%
Past Growth
107%
Estimated Growth
Estimates Accuracy
-1%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Santhera Pharmaceuticals Holding AG

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
29%
Average Beat
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Santhera Pharmaceuticals Holding AG

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-43%
Average Miss
What are analyst estimates?

See Also

Summary
SANN intrinsic value, competitors valuation, and company profile.
DCF Valuation
SANN stock valuation using Discount Cash Flow valuation method.
Relative Valuation
SANN stock valuation using valuation multiples.
Wall Street Estimates
SANN price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
SANN stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is SANN's stock price target?
Price Target
30.6 CHF

According to Wall Street analysts, the average 1-year price target for SANN is 30.6 CHF with a low forecast of 30.3 CHF and a high forecast of 31.5 CHF.

What is Santhera Pharmaceuticals Holding AG's Revenue forecast?
Projected CAGR
107%

For the last 8 years the compound annual growth rate for Santhera Pharmaceuticals Holding AG's revenue is 14%. The projected CAGR for the next 4 years is 107%.

ALPHA SPREAD
Join more than 133,700+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.